Shattuck Labs Inc. Common Stock (STTK)
Stock · NASDAQ · Health Care
$5.44as of 10/16/2026
Price chart
Active signals
STTK Signal Track Record
How signals performed across all stocks →What STTK's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 46 | -0.1% | 50% | September 18, 2026 |
| Bollinger Band Breakout | 22 | +6.3% | 59% | August 25, 2026 |
| Bollinger Band Breakdown | 19 | -3.9% | 42% | September 9, 2026 |
| 200-Day Moving Average TouchActive now | 4 | -8.3% | 25% | October 6, 2026 |
| Any 20-session window (baseline) | -0.7% | 49% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About STTK
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 40
- Website
- www.shattucklabs.com/
Fundamentals
- 1-day range
- $5.27$5.54
- Market cap
- $549.03M
- P/E (trailing)
- —
- P/E (forward)
- -10.48
- EPS (trailing)
- $-0.51
- Dividend yield
- —
- Beta
- 0.97
- Avg. volume
- 1.16M
How Shattuck Labs Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 5, 2026 · via SEC EDGAR / Finnhub
Forecasts
10 analyst ratings
Shattuck Labs Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- STTKShattuck Labs Inc. Common Stock$5.42▼ 1.99%Market cap $549.03MP/E —$1.7$8.33
- SLNSilence Therapeutics Plc American Depository Share$8.68▼ 7.17%Market cap $548.50MP/E —$1.06$5.99
- SPRYARS Pharmaceuticals Inc. Common Stock$4.02▼ 1.23%Market cap $551.13MP/E —$3.89$13.15
- SGMTSagimet Biosciences Inc. Series A Common Stock$8.02▼ 1.84%Market cap $539.71MP/E —$4.5$11.45
- RLMDRelmada Therapeutics Inc. Common Stock$3.1▼ 3.13%Market cap $563.26MP/E —$1.8$8
- ARVNArvinas Inc. Common Stock$6.97▼ 2.65%Market cap $567.55MP/E 50.48$6.74$14.51
- CTNMContineum Therapeutics Inc. Class A Common Stock$7.08▼ 10.38%Market cap $577.48MP/E —$7.96$17.79
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| STTK Shattuck Labs Inc. Common Stock | $549.03M | — | $5.42 | ▼ 1.99% | $1.7$8.33 |
| SLN Silence Therapeutics Plc American Depository Share | $548.50M | — | $8.68 | ▼ 7.17% | $1.06$5.99 |
| SPRY ARS Pharmaceuticals Inc. Common Stock | $551.13M | — | $4.02 | ▼ 1.23% | $3.89$13.15 |
| SGMT Sagimet Biosciences Inc. Series A Common Stock | $539.71M | — | $8.02 | ▼ 1.84% | $4.5$11.45 |
| RLMD Relmada Therapeutics Inc. Common Stock | $563.26M | — | $3.1 | ▼ 3.13% | $1.8$8 |
| ARVN Arvinas Inc. Common Stock | $567.55M | 50.48 | $6.97 | ▼ 2.65% | $6.74$14.51 |
| CTNM Contineum Therapeutics Inc. Class A Common Stock | $577.48M | — | $7.08 | ▼ 10.38% | $7.96$17.79 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- UBS Initiates Coverage On Shattuck Labs with Buy Rating, Announces Price Target of $17benzinga · 10/12/2026
- Wedbush Maintains Outperform on Shattuck Labs, Raises Price Target to $14Benzinga · 10/2/2026
- Abbott To Rally Over 31%? Here Are 10 Top Analyst Forecasts For FridayBenzinga · 10/2/2026
- Needham Maintains Buy on Shattuck Labs, Raises Price Target to $19Benzinga · 10/2/2026
- Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical DevelopmentYahoo · 10/1/2026
Insider Activity
Insider Actions →- Shukla Abhinav A. · July 6, 2026 · Option Exercise12.2K @ $3.57
- Shukla Abhinav A. · July 2, 2026 · Option Exercise410 @ $3.57
- Shukla Abhinav A. · July 2, 2026 · Sale410 @ $7.01
- Shukla Abhinav A. · July 1, 2026 · Sale100 @ $7.07
- Shukla Abhinav A. · July 1, 2026 · Option Exercise100 @ $3.57
- Shukla Abhinav A. · June 30, 2026 · Sale23.4K @ $7.08
- Pandite Arundathy N. · June 30, 2026 · Sale30.0K @ $7.01
- Shukla Abhinav A. · June 30, 2026 · Option Exercise23.4K @ $3.57
- Ashiya Mona · June 11, 2026 · Buy208.3K
- Ashiya Mona · June 11, 2026 · Buy1.04M
- ORBIMED ADVISORS LLC · June 11, 2026 · Buy208.3K
- ORBIMED ADVISORS LLC · June 11, 2026 · Buy1.04M
- Clay B. Siegall · June 9, 2026 · Buy62.5K @ $4
- Ashiya Mona · June 8, 2026 · Conversion3.07M
- Ashiya Mona · June 8, 2026 · Conversion15.37M
Institutional Ownership
March 31, 2026
- Total shares held
- 55.72M
- Total value held
- $279.28M
- Institutional holders
- 81
- Unknown9.87M
- Unknown6.31M
- Unknown5.54M
- Unknown5.00M
- Unknown4.64M
- Unknown3.15M
- Unknown2.28M
- Unknown1.78M
- Unknown1.48M
- Unknown1.37M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
UBS initiates coverage on Shattuck Labs with $17 price target
UBS has started covering Shattuck Labs, assigning a price target of $17. This new analyst view comes as the company prepares to present research at UEG Week 2026. The stock is currently trading near its 52-week low, making this fresh institutional attention a notable development for the company.
UBS initiates coverage on Shattuck Labs with $17 price target. UBS has started covering Shattuck Labs, assigning a price target of $17. This new analyst view comes as the company prepares to present research at UEG Week 2026. The stock is currently trading near its 52-week low, making this fresh institutional attention a notable development for the company.